Amarantus BioSciences, Inc. Strengthens Balance Sheet With Preferred Stock Transaction
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUNNYVALE, Calif., Aug. 19, 2013 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced the Company has entered into an equity financing arrangement with Dominion Capital to settle approximately $1,200,000 in accounts payable in exchange for Series D Preferred Shares of the Company. The transaction substantially reduces the Company's outstanding accounts payable balance, allowing the Company to use cash to fund ongoing operations, primarily product development activities.
Help employers find you! Check out all the jobs and post your resume.
SUNNYVALE, Calif., Aug. 19, 2013 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced the Company has entered into an equity financing arrangement with Dominion Capital to settle approximately $1,200,000 in accounts payable in exchange for Series D Preferred Shares of the Company. The transaction substantially reduces the Company's outstanding accounts payable balance, allowing the Company to use cash to fund ongoing operations, primarily product development activities.
Help employers find you! Check out all the jobs and post your resume.